Elanco Animal Health (NYSE:ELAN) Sets New 12-Month High – Still a Buy?

Elanco Animal Health Incorporated (NYSE:ELAN)’s stock price reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $19.36 and last traded at $19.37, with a volume of 988477 shares traded. The stock had previously closed at $18.92.

Analysts Set New Price Targets

ELAN has been the topic of several research analyst reports. UBS Group increased their price target on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a “buy” rating in a report on Friday, August 8th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Leerink Partnrs raised shares of Elanco Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 17th. William Blair raised Elanco Animal Health from a “market perform” rating to an “outperform” rating in a research note on Thursday, June 26th. Finally, Piper Sandler boosted their target price on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.33.

Elanco Animal Health Price Performance

The company’s 50-day simple moving average is $17.19 and its 200-day simple moving average is $13.76. The stock has a market capitalization of $9.75 billion, a price-to-earnings ratio of 22.82, a P/E/G ratio of 3.64 and a beta of 1.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.20 by $0.06. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. During the same period last year, the firm earned $0.30 EPS. Elanco Animal Health’s revenue for the quarter was up 4.8% on a year-over-year basis. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS. Research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Institutional Trading of Elanco Animal Health

Hedge funds have recently modified their holdings of the company. Nuveen LLC acquired a new stake in shares of Elanco Animal Health during the 1st quarter worth $115,212,000. Dimensional Fund Advisors LP raised its holdings in shares of Elanco Animal Health by 14.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 20,464,727 shares of the company’s stock valued at $214,875,000 after purchasing an additional 2,563,740 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Elanco Animal Health by 322.0% in the 2nd quarter. Jennison Associates LLC now owns 3,234,717 shares of the company’s stock valued at $46,192,000 after acquiring an additional 2,468,122 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after buying an additional 2,445,872 shares during the period. Finally, ASR Vermogensbeheer N.V. acquired a new position in shares of Elanco Animal Health in the 1st quarter valued at $23,744,000. Institutional investors own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.